Home › Non-Small Cell Lung Cancer › Washington
Non-Small Cell Lung Cancer clinical trials in Washington
84 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Washington.
Cities in Washington
- Seattle53 studies
- Tacoma20 studies
- Spokane Valley14 studies
- Spokane12 studies
- Kirkland11 studies
- Vancouver9 studies
- Renton8 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Valley Medical Center, Renton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06623422Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Northwest Medical Specialties - Gig Harbor, Gig Harbor
- Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup
- Northwest Medical Specialties - Tacoma, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06472245The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
- Northwest Cancer Specialists - Vancouver /ID# 277855, Vancouver
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07155187Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0384, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- University of Washington - Fred Hutchinson Cancer Center, Seattle
- Compass Oncology, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Vista Oncology - East Olympia /ID# 275438, Olympia
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Swedish Cancer Institute, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05498428Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C., Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Vista Oncology Inc PS, Olympia
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Vista Oncology, Olympia
- Summit Cancer Centers, Spokane
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Aberdeen
- Research Site, Renton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
- Cancer Care Northwest - Vercler, Spokane Valley
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Northwest Medical Specialties, Tacoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Pan-tumor MRD Study
- Northwest Medical Specialties (NWMS), Tacoma
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0515, Edmonds
- Local Institution - 0499, Lacey
- Local Institution - 0508, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Tacoma
- Research Site, Vancouver
- Research Site, Wenatchee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Edmonds
- Research Site, Seattle
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Valley Medical Center /ID# 253950, Renton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT04928846A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06568939Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- University of Washington Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 22, 2026 · NCT06814496Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Olympia
- Research Site, Seattle
- Research Site, Spokane
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Seattle
- Clinical Study Site, Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Fred Hutchison Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06855771Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Summit Cancer Treatment Center, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06899126Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Vista Oncology - East Olympia /ID# 262303, Olympia
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06236438FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Providence Sacred Heart Medical Center, Spokane
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06303505Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- University of Washington (Data Collection Only), Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT04410796A Study of KK2269 in Adult Participants With Solid Tumors
- University of Washington, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06266299From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.